| 1 | Consumer Staples | XLP | +3.8% |
| 2 | Utilities | XLU | +1.6% |
| 3 | Real Estate | XLRE | +1.0% |
| 4 | Healthcare | XLV | -1.0% |
| 5 | Financials | XLF | -2.6% |
| 6 | Consumer Disc. | XLY | -2.7% |
| 7 | Materials | XLB | -5.8% |
| 8 | Industrials | XLI | -7.1% |
| 9 | Communication | XLC | -8.2% |
| 10 | Energy | XLE | -11.2% |
| 11 | Technology | XLK | -21.0% |
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. …
| Quarter | Date | EPS est. | Actual | Surprise | YoY | Rev. est. | Actual | Surprise | YoY | Copy |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 '26 | 11/10/267:00 AM | -$0.51 | -$0.58GAAP | -13.7% | — | — | $0 | — | — | |
| Q2 '26 | 8/11/267:00 AM | -$0.78 | -$0.80GAAP | -2.6% | -97%* | — | $0 | — | — | |
| Q1 '26 | 5/21/267:00 AM | — | -$23.98GAAP | — | -48% | — | $0 | — | — |
* Q2 '26: Year-ago EPS (-12.91) was before the IPO, on far fewer shares. Restated to today's share count from SEC filings: -0.406.
GAAP = diluted EPS as filed with the SEC.